NEW YORK, May 16, 2019 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Takeda Pharmaceutical Company Ltd. (“Takeda” or the “Company”) (NYSE: TAK). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/tak.

The investigation concerns whether Takeda and certain of its officers and/or directors have violated federal securities laws.

On May 14, 2019, Takeda forecast an unexpected operating loss for the current year, citing costs associated with the Company’s $59 billion purchase of Shire Plc.  On this news, Takeda’s American depositary receipt price fell $1.57 per share, or 8.06%, to close at $17.92 on May 14, 2019.

If you are aware of any facts relating to this investigation, or purchased Takeda shares, you can assist this investigation by visiting the firm’s site: www.bgandg.com/tak. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.